Want to see ATHE full AI Analyst Report?
Top Page
Alterity Therapeutics
(NASDAQ:ATHE)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.50
â–˛(0.67% Upside)
Action:Reiterated
Date:08/30/26
The score is held down primarily by weak financial performance (zero revenue in FY2026, large losses, and heavy cash burn), only partly offset by a low-debt balance sheet. Technicals are neutral-to-weak with the stock trading below key short- and mid-term moving averages, and valuation remains constrained due to negative earnings and no dividend.
Positive Factors
ATH434 Intellectual Property
Long-duration patent protection can preserve future exclusivity for ATH434, improve its strategic value for partnerships, and support commercial potential if Phase 3 and regulatory approval succeed.
Negative Factors
No Current Revenue and Large Losses
The absence of recurring product revenue leaves the company dependent on clinical success and future financing, while sustained operating losses show that commercial earnings power remains unproven.
Read all positive and negative factors
Positive Factors
Negative Factors
ATH434 Intellectual Property
Long-duration patent protection can preserve future exclusivity for ATH434, improve its strategic value for partnerships, and support commercial potential if Phase 3 and regulatory approval succeed.
Read all positive factors
Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$82.78M
Dividend YieldN/A
Average Volume (3M)13.54K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS Growth96.65%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding18,391,737
10 Day Avg. Volume22,745
30 Day Avg. Volume13,538
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)3.19
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside179.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$2.50M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent e...
How the Company Makes Money
null...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.44M | 4.02M | 3.92M | 5.12M |
| Gross Profit | -113.01K | 5.31M | 3.80M | 3.63M | 4.76M |
| EBITDA | -27.69M | -14.63M | -19.57M | -14.60M | -17.39M |
| Net Income | -22.89M | -12.15M | -19.12M | -13.81M | -12.85M |
Balance Sheet | |||||
| Total Assets | 46.02M | 46.03M | 19.22M | 27.32M | 41.36M |
| Cash, Cash Equivalents and Short-Term Investments | 37.32M | 40.66M | 12.64M | 15.77M | 34.81M |
| Total Debt | 193.47K | 155.46K | 159.04K | 210.38K | 117.49K |
| Total Liabilities | 3.29M | 3.62M | 5.43M | 4.50M | 5.89M |
| Stockholders Equity | 42.73M | 42.40M | 13.80M | 22.81M | 35.47M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -11.45M | -12.61M | -20.04M | -12.43M |
| Operating Cash Flow | -22.03M | -11.45M | -12.61M | -20.04M | -12.34M |
| Investing Cash Flow | 7.34M | -7.50M | -5.72K | -36.46K | -89.15K |
| Financing Cash Flow | 18.71M | 39.67M | 9.22M | 124.34K | 16.30M |
Alterity Therapeutics Technical Analysis
Neutral
4.47
Price Trends
4.80
Negative
4.60
Negative
4.00
Positive
Market Momentum
-0.05
Positive
47.17
Neutral
23.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Neutral. The current price of 4.47 is below the 20-day moving average (MA) of 4.61, below the 50-day MA of 4.80, and above the 200-day MA of 4.00, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 47.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATHE.
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $85.18M | -1.95 | -71.71% | ― | ― | 73.44% | |
46 Neutral | $144.57M | -3.17 | -88.81% | ― | ― | 43.63% | |
44 Neutral | $29.02M | -0.62 | -202.14% | ― | ― | 73.69% | |
43 Neutral | $82.78M | -4.57 | -48.25% | ― | ― | 96.65% |
* Healthcare Sector Average
ATHE
Alterity Therapeutics
4.52
-0.56
-11.02%
CVM
Cel-Sci
1.61
-9.63
-85.68%
XBIT
XBiotech
2.20
-0.78
-26.17%
KLRS
Kalaris Therapeutics
3.94
-0.72
-15.45%
UNCY
Unicycive Therapeutics
5.30
0.98
22.69%
Alterity Therapeutics Corporate Events
Alterity Therapeutics Seeks Quotation of ATH Securities in August 2026
Aug 14, 2026
Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission in August 2026, documenting an application for quotation of its securities under the ticker ATH. The filing, signed by Chairman Julian Babarczy on August 14, 2...
Alterity Therapeutics Wins Long-Term U.S. Patent Protection for Lead MSA Drug ATH434
Aug 13, 2026
On August 12, 2026, Alterity Therapeutics announced that the U.S. Patent and Trademark Office granted a new composition of matter patent covering a crystalline mesylate form of its lead asset ATH434, including associated treatment methods for neur...
Alterity Therapeutics Files August 3 Application to Quote ATH Securities
Aug 4, 2026
Alterity Therapeutics Limited, an Australia-based development-stage biopharmaceutical company, operates as a foreign private issuer on U.S. markets and relies on multiple SEC registration statements to support investor access. The company’s ...
Alterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA
Jul 30, 2026
In the quarter ended 30 June 2026, Alterity Therapeutics secured key regulatory progress for its lead MSA candidate ATH434, with U.S. FDA End-of-Phase 2 meeting minutes confirming a clear registrational pathway. The agency indicated that a single ...
Alterity Therapeutics Files Form 6-K and Seeks Quotation for ATH Securities
Jul 21, 2026
On July 21, 2026, Alterity Therapeutics Limited filed a Form 6-K with the U.S. Securities and Exchange Commission, reporting as a foreign private issuer for the month of July 2026. The filing confirms the company continues to rely on existing Form...
Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026
Jul 21, 2026
Alterity Therapeutics announced on July 21, 2026, that Chief Executive Officer David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29. During the event, Dr. Stamler plans to hold one-on-on...
Alterity Therapeutics Secures FDA-Confirmed Registrational Pathway for ATH434 in Multiple System Atrophy
Jul 7, 2026
On July 7, 2026, Alterity Therapeutics announced it has received official U.S. Food and Drug Administration End-of-Phase 2 meeting minutes confirming the registrational pathway for its lead drug candidate ATH434 in Multiple System Atrophy. The FDA...
Alterity Therapeutics Files July Form 6-K for Quotation of ATH Securities
Jul 1, 2026
On July 1, 2026, Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission, signaling an application for quotation of its securities under the ticker ATH. The filing, signed by Chairman Julian Babarczy, indicates the ...
Alterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing
Jun 30, 2026
Alterity Therapeutics Limited reported a change in substantial holding in a Form 6-K filing with the U.S. Securities and Exchange Commission for June 2026, signed by Chairman Julian Babarczy on June 30, 2026. The disclosure, made via Exhibit 99.1,...
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
Jun 17, 2026
Alterity Therapeutics reported on June 17, 2026, that it had filed a Form 6-K with the U.S. Securities and Exchange Commission as a foreign private issuer, updating its disclosure record for the month of June 2026. The filing primarily serves to l...
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
Jun 16, 2026
Alterity Therapeutics on June 16, 2026, filed a Form 6-K with the U.S. Securities and Exchange Commission, indicating the submission of a new corporate presentation dated June 2026 as an exhibit. The filing, signed by Chairman Julian Babarczy, als...
Alterity Therapeutics Files Form 6-K on Unquoted Securities Notification
Jun 15, 2026
Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission on June 15, 2026, as a routine report for a foreign private issuer. The filing discloses the submission of a notification regarding unquoted securities under t...
Alterity Therapeutics Files June Form 6-K Highlighting Cessation of Certain Securities
Jun 15, 2026
Alterity Therapeutics Limited reported on June 15, 2026 that it had submitted a Form 6-K to the U.S. Securities and Exchange Commission for the month of June as a foreign private issuer. The filing incorporates the report by reference into several...
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
Jun 12, 2026
Alterity Therapeutics, listed on the ASX and Nasdaq, develops disease-modifying therapies for neurodegenerative disorders, notably Multiple System Atrophy, from bases in Melbourne and San Francisco. Its lead drug candidate ATH434 has produced posi...
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
Jun 9, 2026
Alterity Therapeutics, which operates from Melbourne and San Francisco, is advancing a pipeline that centers on ATH434 for MSA, a rare and rapidly progressive Parkinsonian disorder with no approved disease-modifying therapies. Its Phase 2 program ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.